SCHEMBL25811801

SCHEMBL25811801

Cc1[nH]c2ccc(C(=O)N(C)CCN3CCCC3)cc2c1C

nearest known ligand 0.62

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.61
RAB9A P51151 2/20 0.57
SMN1; SMN2 Q16637 2/20 0.57
NPC1 O15118 1/20 0.57
GFER P55789 1/20 0.57
KDM4E B2RXH2 3/20 0.50
ALDH1A1 P00352 3/20 0.50
HPGD P15428 2/20 0.50
THRB P10828 1/20 0.50
HCRTR1 O43613 1/20 0.48
ALOX15 P16050 1/20 0.46
CASP1 P29466 1/20 0.46
HSD17B10 Q99714 1/20 0.46
MEN1 O00255 1/20 0.44
POLB P06746 2/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
MAPT P10636 3/20 0.43
TP53 P04637 1/20 0.43
HSP90AA1 P07900 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25811987 0.98 KMT2A (0.58) KMT2ARAB9ASMN1; SMN2NPC1GFER
SCHEMBL25814483 0.90 ALDH1A1 (0.53) KMT2ARAB9ASMN1; SMN2NPC1GFER
SCHEMBL25811995 0.87 KMT2A (0.49) KMT2ARAB9ASMN1; SMN2NPC1GFER
SCHEMBL25812014 0.87 KMT2A (0.49) KMT2ARAB9ASMN1; SMN2NPC1GFER
SCHEMBL25814895 0.87 KMT2A (0.61) KMT2ARAB9ASMN1; SMN2NPC1GFER
SCHEMBL25814053 0.86 TLR9 (0.46) KMT2ARAB9ASMN1; SMN2NPC1GFER
SCHEMBL25815032 0.86 KMT2A (0.45) KMT2ARAB9ASMN1; SMN2NPC1GFER
SCHEMBL25813827 0.82 KDM4E (0.58) KMT2ARAB9ASMN1; SMN2NPC1GFER
SCHEMBL25811968 0.81 LMNA (0.54) KMT2ARAB9ASMN1; SMN2NPC1KDM4E
SCHEMBL25811972 0.81 LMNA (0.51) KMT2ARAB9ASMN1; SMN2NPC1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230218573-A1 INDOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES GALYAN BIO INC (US) 2023-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230218573-A1 INDOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES HTT, HYPK, PARK7 KMT2A 981/4885RAB9A 729/4885SMN1; SMN2 156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.